France· FR:67868413
RYDAPT 25 mg, capsule molle
A medicinal product containing midostaurine, registered in France by NOVARTIS EUROPHARM (IRLANDE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MIDOSTAURINE
- Manufacturer
- NOVARTIS EUROPHARM (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip133400930113608Conditionnements multiples de 112 (4 boîtes de 28) capsules sous plaquettes polyamide aluminium PVC-AluminiumEUR 10.7
- cip133400930129821Conditionnements multiples de 56 (2 boîtes de 28) capsules sous plaquettes polyamide aluminium PVC-AluminiumEUR 5.42
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Midostaurine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandRydaptOrifarm Oy
- CzechiaRYDAPTNovartis Europharm Limited, Dublin
- SwitzerlandRydapt 25 mg, WeichkapselnNovartis Pharma Schweiz AG
- United StatesRYDAPTNovartis Pharmaceuticals Corporation
- NorwayRydaptNovartis Europharm Limited (1)
- PolandRydaptNovartis Europharm Limited
- SwedenRydapt 25 mg Kapsel, mjukNovartis Europharm Limited
- IrelandRydapt 25 mg soft capsulesNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rydapt
- Liechtenstein · Rydapt
- Norway · Rydapt
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8cf84521-a835-4872-b809-ad8360a7bd4c GET /v1/drugs/8cf84521-a835-4872-b809-ad8360a7bd4c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67868413",
"date_amm": "2017-09-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1218",
"substance": "MIDOSTAURINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "capsule molle",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about midostaurine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.